

## **Keynote: Ethics and oncology**

*Dr. Scott Berry*

At the completion of this session, the learner will:

1. Comprehend the concept of ethical decision making in oncology care;
2. Will comprehend the concept of statistically significant vs clinically meaningful outcomes in oncology clinical trials;
3. Understand what is involved in the decision of whether or not to fund a treatment;
4. Be able to explain this information to a patient.

## **Parp inhibitors in oncology care (Symposium)**

*Speaker TBA*

At the completion of this session, the learner will be able to:

1. Evaluate the recent evidence regarding the role of PARP inhibitors in the systemic treatment of metastatic breast, ovary, and prostate cancers;
2. List the expected toxicities of parp inhibitor drugs and their management;
3. Discuss the indication for PARP inhibitors with patients.

## **Genetics and oncology – Which panel / which patient**

*Dr. Kathleen Buckley*

At the completion of this session, the learner will be able to:

1. Recognize the role and importance of genetic testing in the treatment plan for oncology patients;
2. Determine which patients require genetic assessment (testing, evaluation);
3. Explain the rationale for genetic testing to patients, discuss the result(s) and refer to a genetic counsellor when appropriate.

## **Hematology – Multiple myeloma**

*Dr. Amy Tam*

At the completion of this session, the learner will:

1. Comprehend how the treatment of multiple myeloma has evolved including criteria for treatment-based patient selection in those individuals who are not candidates for stem cell transplant;
2. Understand how protease inhibitors and immunomodulatory drugs are used during induction and post transplant maintenance;
3. Be able to discuss and manage expected toxicities of these agents.

## **MAID update**

*Dr. Marnie Howe*

At the completion of this session, the learner will:

1. Understand the recent changes to the criteria for the delivery of MAID;
2. Comprehend how to reply to a patient who requests MAID;
3. Be able to discuss what effects the pandemic has had on access and delivery of MAID during the pandemic.



### **Lung – Lung cancer treatment update**

*Dr. Hamid Mithoowani*

At the completion of this session, the learner will:

1. Be able to discuss the latest advancements in the treatment of both small cell and non-small cell lung cancer;
2. Develop awareness of toxicities associated with these new treatments and their management;
3. Be able to apply this knowledge to their practice.

### **Cancer patient journey and its polypharmacy: What to consider for the management of cancer-associated thrombosis (Symposium)**

*Speaker – TBD*

At the completion of this session, the learner will be able to:

1. Understand the evolution of anti-cancer therapies and the challenges/considerations of polypharmacy throughout the journey of a patient with malignancy
2. Review the latest evidence on bleeding and thrombotic risks when selecting an anticoagulant for the management of patients on anticancer therapies

### **ASCO/ESMO update and CTCs**

*Dr. Andrea Molckovsky*

At the completion of this session, the learner will be able to:

1. List three to four practice changing outcomes from ASCO 2022 and ESMO 2022;
2. Explain how the data presented can be applied to their patient population;
3. Discuss the evolving evidence for circulating tumor cells in oncology treatment protocols.

### **Breast – Gene assays: Which/when/why**

*Dr. Henry Contour*

At the completion of this session, the learner will be able to:

1. List the various gene assays available for use in the management of breast cancer;
2. Distinguish between these assays regarding their utility in treatment decision-making, based on the evidence;
3. Explain to patients the rationale for recommending an individual test and how the result(s) influence(s) their treatment recommendation.

### **Electrolyte abnormalities & pharmacy pearls**

*Mona Abdullah*

At the completion of this session, the learner will:

1. Understand outpatient management of electrolyte abnormalities, focusing on which choice of agents to correct the abnormality, appropriate dosing and length of therapy;
2. Become aware of online resources that can assist with toxicity management



### **Geriatric assessment in oncology (Symposium)**

*Dr. Anu Batra*

At the completion of this session, the learner will:

1. Have gained knowledge of the various domains that need to be evaluated prior to considering the appropriateness of systemic therapy in geriatric patients;
2. Comprehend the various tools used to predict outcomes including adverse events in geriatric oncology patients;
3. Recognize the factors influencing treatment modifications in the geriatric population and adapt this knowledge into practice.

### **Breast – Her2 treatment in adjuvant and metastatic settings**

*Dr Nadia Califaretti*

At the completion of this session, the learner will be able to:

1. Interpret the evidence supporting the role of Her2 based therapies in the adjuvant and metastatic setting;
2. Explain to patients the rationale for various Her2 based therapies (single and combination), their benefits and side effects as well as the long-term outcomes of usage;
3. Implement appropriate toxicity monitoring (including cardiac) in the short and long-term treatment phase.

### **GI – Rectal treatment: Stage 3 and metastatic disease**

*Dr. Oren Levine*

At the completion of this session, the learner will:

1. Understand the various regimens for treating rectal cancers, focusing on Opra and Rapido
2. Be able to discuss patient selection, protocol design, common toxicity management and follow-up care

### **Radiation oncology milestones**

*Dr. Darin Gopaul*

At the completion of this session, the learner will:

1. List three practice changing developments from radiation oncology clinical trials in the last five years;
2. Explain how data presented can be applied to their patient population.

### **COVID & how it affects oncology care**

*Dr. Hamid Mithoowani*

At the completion of this session, the learner will be able to:

1. Summarize the major effects (positive and negative) that the COVID pandemic has exerted on the provision of oncology care and on the health care system;
2. Explain to patients how this/these effect(s) impact(s) on treatment outcomes;
3. Discuss the impact the pandemic has had in altering various treatment regimens (length, dosing, schedule).